Actinium Pharmaceuticals (ATNM) Return on Sales (2021 - 2026)

Actinium Pharmaceuticals (ATNM) posted quarterly Return on Sales of 2.63% for Q4 2025, down 274.53% quarter-over-quarter from 0.7% in Q3 2025.

Actinium Pharmaceuticals (ATNM) Return on Sales (2021 - 2026) Analysis & Trends

Actinium Pharmaceuticals (ATNM) has reported Return on Sales for 3 consecutive years, with 2.63% the latest figure, recorded in Q4 2025.

In Q4 2025, Return on Sales changed N/A year-over-year to 2.63%; the TTM figure through Dec 2025 stood at 2.63% (changed N/A YoY), while the FY2025 annual figure was 3.7%, changed N/A from the prior year.
Return on Sales retreated to 2.63% in Q4 2025 per ATNM's latest filing, from 0.7% in the prior quarter.
Across five years, Return on Sales topped out at 0.06% in Q1 2022 and bottomed at 3.54% in Q4 2021.
Historically, Return on Sales has averaged 1.31% across 3 years, with a median of 0.54% in 2022.
On a YoY basis, Return on Sales climbed as much as 316 bps in 2022 and fell as far as 300 bps in 2022.
Actinium Pharmaceuticals' Return on Sales stood at 3.54% in 2021, then surged by 89 bps to 0.38% in 2022, then plunged by 583 bps to 2.63% in 2025.
Business Quant data shows ATNM's Return on Sales at 2.63% in Q4 2025, 0.7% in Q3 2025, and 0.38% in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	139.77 Bn	131.91 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	86.74 Bn	78.75 Bn	3.93 Bn	0.00%
3	Argenx Se	65.36 Bn	60.17 Bn	1.37 Bn	0.00%
4	Moderna	59.60 Bn	54.47 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.80 Bn	28.49 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.13 Bn	9.73 Bn	668.28 Mn	0.00%
8	Insmed	27.54 Bn	26.38 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.31 Bn	26.47 Bn	-	0.00%
10	Actinium Pharmaceuticals	35.64 Mn	35.64 Mn	-	0.01%

Download Data